Genomic landscape of extraordinary responses in metastatic breast cancer
Extreme responders to anticancer therapy are rare among advanced breast cancer patients. Researchers, however, have yet to investigate treatment responses therein on the whole exome level. We performed whole exome analysis to characterize the genomic landscape of extreme responders among metastatic breast cancer patients. Clinical samples were obtained from breast cancer patients who showed exceptional responses to anti-HER2 therapy or hormonal therapy and from those who did not. Matched breast tumor tissue (somatic DNA) and blood samples (germline DNA) were collected from a total of 30 responders and 15 non-responders. Whole exome sequencing using Illumina HiSeq2500 was performed for all 45 patients (90 samples). Somatic single nucleotide variants (SNVs), indels, and copy number variants (CNVs) were identified for the genomes of each patient. Group-specific somatic variants and mutational burden were statistically analyzed. Sequencing of cancer exomes for all patients revealed 1839 somatic SNVs (1661 missense, 120 nonsense, 43 splice-site, 15 start/stop-lost) and 368 insertions/deletions (273 frameshift, 95 in-frame), with a median of 0.7 mutations per megabase (range, 0.08 to 4.2 mutations per megabase). Responders harbored a significantly lower nonsynonymous mutational burden (median, 26 vs. 59, P = 0.02) and fewer CNVs (median 13.6 vs. 97.7, P = 0.05) than non-responders. Multivariate analyses of factors influencing progression-free survival showed that a high mutational burden and visceral metastases were significantly related with disease progression. Extreme responders to treatment for metastatic breast cancer are characterized by fewer nonsynonymous mutations and CNVs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:4 |
|---|---|
| Enthalten in: |
Communications biology - 4(2021), 1 vom: 09. Apr., Seite 449 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lim, Sun Min [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 05.08.2021 Date Revised 07.12.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s42003-021-01973-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM32392333X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM32392333X | ||
| 003 | DE-627 | ||
| 005 | 20231225185222.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s42003-021-01973-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1079.xml |
| 035 | |a (DE-627)NLM32392333X | ||
| 035 | |a (NLM)33837242 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lim, Sun Min |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Genomic landscape of extraordinary responses in metastatic breast cancer |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.08.2021 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Extreme responders to anticancer therapy are rare among advanced breast cancer patients. Researchers, however, have yet to investigate treatment responses therein on the whole exome level. We performed whole exome analysis to characterize the genomic landscape of extreme responders among metastatic breast cancer patients. Clinical samples were obtained from breast cancer patients who showed exceptional responses to anti-HER2 therapy or hormonal therapy and from those who did not. Matched breast tumor tissue (somatic DNA) and blood samples (germline DNA) were collected from a total of 30 responders and 15 non-responders. Whole exome sequencing using Illumina HiSeq2500 was performed for all 45 patients (90 samples). Somatic single nucleotide variants (SNVs), indels, and copy number variants (CNVs) were identified for the genomes of each patient. Group-specific somatic variants and mutational burden were statistically analyzed. Sequencing of cancer exomes for all patients revealed 1839 somatic SNVs (1661 missense, 120 nonsense, 43 splice-site, 15 start/stop-lost) and 368 insertions/deletions (273 frameshift, 95 in-frame), with a median of 0.7 mutations per megabase (range, 0.08 to 4.2 mutations per megabase). Responders harbored a significantly lower nonsynonymous mutational burden (median, 26 vs. 59, P = 0.02) and fewer CNVs (median 13.6 vs. 97.7, P = 0.05) than non-responders. Multivariate analyses of factors influencing progression-free survival showed that a high mutational burden and visceral metastases were significantly related with disease progression. Extreme responders to treatment for metastatic breast cancer are characterized by fewer nonsynonymous mutations and CNVs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 700 | 1 | |a Kim, Eunyoung |e verfasserin |4 aut | |
| 700 | 1 | |a Jung, Kyung Hae |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Sora |e verfasserin |4 aut | |
| 700 | 1 | |a Koo, Ja Seung |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Seung Il |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Seho |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Hyung Seok |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Byoung Woo |e verfasserin |4 aut | |
| 700 | 1 | |a Cho, Young Up |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Ji Ye |e verfasserin |4 aut | |
| 700 | 1 | |a Paik, Soonmyung |e verfasserin |4 aut | |
| 700 | 1 | |a Kwon, Nak-Jung |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Gun Min |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Ji Hyoung |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Min Hwan |e verfasserin |4 aut | |
| 700 | 1 | |a Jeon, Min Kyung |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Sangwoo |e verfasserin |4 aut | |
| 700 | 1 | |a Sohn, Joohyuk |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Communications biology |d 2018 |g 4(2021), 1 vom: 09. Apr., Seite 449 |w (DE-627)NLM284287245 |x 2399-3642 |7 nnns |
| 773 | 1 | 8 | |g volume:4 |g year:2021 |g number:1 |g day:09 |g month:04 |g pages:449 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s42003-021-01973-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 4 |j 2021 |e 1 |b 09 |c 04 |h 449 | ||